182 related articles for article (PubMed ID: 894039)
1. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
2. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
3. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
4. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
5. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
6. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
Arroyave CM; Wilson MR; Tan EM
J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
[TBL] [Abstract][Full Text] [Related]
7. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
Wahn V; Müller W; Rieger C; Rother U
Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
[TBL] [Abstract][Full Text] [Related]
8. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
9. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
10. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
11. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
12. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
13. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
Whaley K; Ward D; Ruddy S
Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
[TBL] [Abstract][Full Text] [Related]
15. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
[TBL] [Abstract][Full Text] [Related]
16. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
17. Humoral immunostimulation. IV. Role of complement.
Shearer WT; Atkinson JP; Frank MM; Parker CW
J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
[TBL] [Abstract][Full Text] [Related]
18. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media.
Kolb WP; Lang JH; Lasser EC
J Immunol; 1978 Oct; 121(4):1232-8. PubMed ID: 100552
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
Robertson J; Caldwell JR; Castle JR; Waldman RH
J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
[TBL] [Abstract][Full Text] [Related]
20. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]